Literature DB >> 21982044

Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.

Andreas Brunner1, Susanne Hinterholzer, Paul Riss, Georg Heinze, Hermann Brustmann.   

Abstract

OBJECTIVE: B7-H3, a member of the B7 family of immune regulatory ligands regulates T cell-mediated peripheral immune response. The purpose of this study was to correlate the expression of B7-H3 and number of lymphocytes in patients with endometrial cancer.
MATERIAL AND METHODS: A total of 107 patients with primary endometrial carcinoma (type I/endometrioid, n=81; type II, n=18) and endometrial hyperplasia (n=8) were investigated. Expression of B7-H3 in endometrial hyperplasia, endometrial carcinoma, and the endothelium of tumor-associated vasculature was assessed using immunohistochemistry from paraffin-embedded tissue blocks. Detection of CD8-positive tumor-infiltrating lymphocytes (TIL) and CD8-positive tumor-associated lymphocytes (TAL) was correlated with the expression of B7-H3.
RESULTS: Patients with high grade tumors and patients with type II carcinomas expressed significantly more B7-H3 than low grade and endometrioid tumors (p=<0.0001 and p=0.0001, respectively). The expression of B7-H3 in the endothelium of identified vasculature in the tumor specimens showed similar results with strong relation to high grade tumors (p=0.001) and type II carcinomas (p=0.004). We found a significant correlation between B7-H3 expression on cancer cells and tumor T-cell infiltration (TIL) (p=0.017). In a univariate survival analysis, overexpression of B7-H3 in tumor cells was associated with shortened overall survival (p=0.005).
CONCLUSIONS: B7-H3 is overexpressed on cancer cells and in the endothelium of tumor-associated vasculature in high grade tumors (G3) and type II carcinomas. B7-H3 expression on cancer cells is correlated with the number of T cells infiltrating the tumor. Endometrium tumor development and progression may be associated with downregulation of T-cell-mediated antitumor immunity through B7-H3.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982044     DOI: 10.1016/j.ygyno.2011.09.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  38 in total

1.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

2.  Evaluation of ductal carcinoma in situ grade via triple-modal molecular imaging of B7-H3 expression.

Authors:  Sunitha Bachawal; Gregory R Bean; Gregor Krings; Katheryne E Wilson
Journal:  NPJ Breast Cancer       Date:  2020-04-29

3.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

4.  Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.

Authors:  Ting Zhang; Bo Jiang; Shi-Tao Zou; Fen Liu; Dong Hua
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

5.  Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging.

Authors:  Sunitha V Bachawal; Kristin C Jensen; Katheryne E Wilson; Lu Tian; Amelie M Lutz; Jürgen K Willmann
Journal:  Cancer Res       Date:  2015-04-21       Impact factor: 12.701

Review 6.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 7.  Endothelial cells in the eyes of an immunologist.

Authors:  M Rita Young
Journal:  Cancer Immunol Immunother       Date:  2012-08-18       Impact factor: 6.968

8.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

9.  Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers.

Authors:  Juanjuan Hu; Caiying Jiang; Meijun Zheng; Yuxin Guo; Xin Tang; Jia Ren; Dan Lu; Lingyu Yu; Weigang Gan; Shixi Liu; Aiping Tong; Hui Yang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 10.  New B7 Family Checkpoints in Human Cancers.

Authors:  Ling Ni; Chen Dong
Journal:  Mol Cancer Ther       Date:  2017-07       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.